Hospital

Long-term data show that early treatment with ofatumumab decreased confirmed disability worsening in nearly all study patients with relapsing multiple sclerosis.

Avapritinib has been FDA approved for the treatment of advanced systemic mastocytosis since June 2021.

Many patients with post-COVID-19 condition reported perceived cognitive deficits early during their COVID-19 infection as well.

Beremagene geperpavec completely closed severe blistering and wounds in more than half of all patients with dystrophic epidermolysis bullosa with specific mutations.

Understanding causes, consequences proves vital to develop therapies that exploit vulnerabilities of the cancer cells.

The results of a recent study suggest that a testing policy change for C. difficile could decrease the risk of additional infections and the corresponding economic burden on the hospital.

Supportive nurse managers and supervisors as well as nurses’ involvement in organizational governance may help lower hospital-onset Clostridioides difficile infection in acute care hospitals.

Findings suggest that mice derived from and breastfed by immunized mothers were capable of producing anti- pneumococcal surface protein A (PspA) specific antibodies, despite having no direct exposure to PspA.

Treatment with epcoritamab-bysp showed a 61% overall response rate and a 38% complete response rate in heavily pretreated patients with R/R DLBCL.

Nanoparticles could improve the solubility of drugs, aid in treatment escape from the immune system, and increase the half-life of drugs in the circulatory system against viral lung infections such as influenza, coronavirus, and respiratory syncytial virus.

PCV10 protection is likely to have reduced the incidence of pneumococcal disease among all ages by between 48% and 66%.

Targeted PrEP advertisements with different types of couples and sociodemographic characteristics were more eye-catching, motivating, relatable, and memorable.

Amid various obstacles, health care providers and pharmacists can initiate measures to enhance compensation for pharmacy services in managed care.

In clinical trials of patients with Crohn disease, upadacitinib demonstrated early and long-term symptom relief, as well a visible reduction of damage to the intestinal lining caused by excess inflammation.

Study finds that a more accurate estimate of the burden of RSV disease will facilitate appropriate decision making regarding the use of preventive interventions, such as vaccination.

Improving awareness and getting involved in local or national initiatives can enable pharmacists to make change.

At least 150 minutes per week of moderate intensity aerobic activity, or 75 minutes of vigorous intensity aerobic activity found to improve outcomes in patients with flu or pneumonia.

The panel corresponds to proteins that are abundant in treatment-resistant melanoma cells and may predict resistance to targeted treatment.

Study findings may help guide efforts to develop effective HIV vaccines and antibody-based HIV treatments.

When considering outsourcing, pharmacies should use a multistakeholder team to weigh pros and cons.

Common chronic pain conditions included in the analysis were fibromyalgia, neuropathic pain, and musculoskeletal pain.

Pegfilgrastim-pbbk is a leukocyte growth factor developed to reduce the onset of infection in patients with non-myeloid malignancies administered myelosuppressive anticancer medications associated with a clinically significant rate of febrile neutropenia.

Preexposure prophylaxis use for HIV continues to be lower than desired in some populations.

Health care professionals should educate patients that it is possible to effectively manage pain without opioids.

Study evaluates the effect of long-acting monoclonal antibodies tixagevimab and cilgavimab treating COVID-19 symptoms and viral shedding.

Hospitalization costs from respiratory syncytial virus infection are driven by older age and comorbidities.

Precision medicine is rooted in the reality that the way patients respond to treatment is heavily affected by their individual genetic variability, their complex biology, and external factors.

Since the 2018 guideline’s publication, additional non-statin therapies such as bempedoic acid, evinacumab, and inclisiran, have been approved by the FDA for the management of hypercholesterolemia.